Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.35 |
| ▸ | F11 | P03951 | 2/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.35 |
| ▸ | LIPE | Q05469 | 8/20 | 0.33 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27212329 | 0.86 | F2 (0.30) | F2F11PRSS1PRSS2PRSS3 | |
| SCHEMBL30050648 | 0.82 | AAK1 (0.38) | LIPE | |
| SCHEMBL24822117 | 0.82 | AAK1 (0.38) | LIPE | |
| SCHEMBL25128559 | 0.76 | ANO1 (0.35) | ANO1SMN1; SMN2MTNR1BMTNR1AALDH1A1 | |
| SCHEMBL25128558 | 0.75 | ANO1 (0.34) | ANO1SMN1; SMN2MTNR1BMTNR1AALDH1A1 | |
| SCHEMBL8403380 | 0.73 | ADRA2A (0.38) | ANO1SMN1; SMN2MTNR1BMTNR1AADRA2A | |
| SCHEMBL30050646 | 0.72 | LMNA (0.36) | — | |
| SCHEMBL24819195 | 0.72 | LMNA (0.36) | — | |
| SCHEMBL29159707 | 0.71 | LMNA (0.35) | F2F11PRSS1PRSS2PRSS3 | |
| SCHEMBL29254037 | 0.69 | LIPE (0.39) | LIPESMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257367-A1 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST | CHENGDU KANGHONG PHARMACEUTICAL CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257367-A1 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST | CHENGDU KANGHONG PHARMACEUTICAL CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| EP-4159723-A1 | NOVEL THYROID HORMONE ß RECEPTOR AGONIST | Chengdu Kanghong Pharmaceutical Co., Ltd. (CN) | 2023-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257367-A1 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST | THRB, THRA, TSHR | F2 2292/4885F11 2442/4885PRSS1 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.